GADOLIN: PRIMARY RESULTS FROM A PHASE III STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE COMPARED WITH BENDAMUSTINE ALONE IN PATIENTS WITH RITUXIMAB-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA

被引：0

作者：

Sehn, L. ^{[1
,2
]}

Chua, N. ^{[3
]}

Mayer, J. ^{[4
]}

Dueck, G. ^{[5
]}

Trneny, M. ^{[6
]}

Bouabdallah, K. ^{[7
]}

Fowler, N. ^{[8
]}

Delwail, V. ^{[9
]}

Press, O. ^{[10
]}

Salles, G. ^{[11
]}

Gribben, J. ^{[12
]}

Lennard, A. ^{[3
]}

Lugtenburg, P. ^{[13
]}

Franklin, N. ^{[14
]}

Wassner-Fritsch, E. ^{[15
]}

Fingerle-Rowson, G. ^{[15
]}

Cheson, B. ^{[16
]}

机构：

[1] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada

[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada

[3] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada

[4] Brno & Masaryk Univ, Univ Hosp, Brno, Czech Republic

[5] BC Canc Agcy, Kelowna, Kelowna, BC, Canada

[6] Charles Univ Prague, Gen Hosp, Prague, Czech Republic

[7] CHU Haut Leveque, Pessac, France

[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[9] Univ Hosp, INSERM, Poitiers, France

[10] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[11] Hosp Civils Lyon, Pierre Benite, France

[12] Queen Mary Univ London, Barts Canc Inst, London, England

[13] Erasmus MC Canc Inst, Rotterdam, Netherlands

[14] F Hoffmann La Roche Ltd, Welwyn Garden City, Herts, England

[15] F Hoffmann La Roche Ltd, Basel, Switzerland

[16] Georgetown Univ Hosp, Washington, DC 20007 USA

来源：

HAEMATOLOGICA | 2015年 / 100卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

LB691

引用

页码：273 / 273

页数：1

共 50 条

[41] Subsequent Primary Malignancies in Patients with Indolent B Cell Non-Hodgkin Lymphoma Receiving Frontline Bendamustine Rituximab Therapy [J].

Davies, Gwynivere A. ;

Prica, Anca ;

Ante, Zharmaine ;

Liu, Ning ;

Pond, Gregory R. ;

Balitsky, Amaris K. ;

Mozessohn, Lee .

BLOOD, 2024, 144 :3749-3750

[42] Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma [J].

Robinson, K. Sue ;

Williams, Michael E. ;

van der Jagt, Richard H. ;

Cohen, Philip ;

Herst, Jordan A. ;

Tulpule, Anil ;

Schwartzberg, Lee S. ;

Lemieux, Bernard ;

Cheson, Bruce D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (27) :4473-4479

[43] Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma [J].

Moosmann, Peter ;

Heizmann, Marc ;

Kotrubczik, Nina ;

Wernli, Martin ;

Bargetzi, Mario .

LEUKEMIA & LYMPHOMA, 2010, 51 (01) :149-152

[44] Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma [J].

Czuczman, Myron S. ;

Kahanic, Stephen ;

Forero, Andres ;

Davis, Glen ;

Munteanu, Mihaela ;

Van den Neste, Eric ;

Offner, Fritz ;

Bron, Dominique ;

Quick, Donald ;

Fowler, Nathan .

ANNALS OF HEMATOLOGY, 2015, 94 (04) :633-641

[45] Phase II results of bendamustine in combination with rituximab in relapsed indolent and mantle-cell non-Hodgkin's lymphoma. [J].

Van der Jagt, Richard H. ;

Cohen, Philip ;

Cheson, Bruce D. ;

Tulpule, Anil ;

Herst, Jordan A. ;

Lemieux, Bernard ;

Schwartzberg, Lee S. ;

Robinson, Katherine Sue ;

Oliver, Jennifer W. ;

Williams, Michael E. .

BLOOD, 2006, 108 (11) :766A-766A

[46] Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin’s lymphoma [J].

Myron S. Czuczman ;

Stephen Kahanic ;

Andres Forero ;

Glen Davis ;

Mihaela Munteanu ;

Eric Van Den Neste ;

Fritz Offner ;

Dominique Bron ;

Donald Quick ;

Nathan Fowler .

Annals of Hematology, 2015, 94 :633-641

[47] A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma [J].

Khan, Khuda D. ;

Emmanouilides, Christos ;

Benson, Don M., Jr. ;

Hurst, Deborah ;

Garcia, Pablo ;

Michelson, Glenn ;

Milan, Sandra ;

Ferketich, Amy K. ;

Piro, Lawrence ;

Leonard, John P. ;

Porcu, Pierluigi ;

Eisenbeis, Charles F. ;

Banks, Amy L. ;

Chen, Lei ;

Byrd, John C. ;

Caligiuri, Michael A. .

CLINICAL CANCER RESEARCH, 2006, 12 (23) :7046-7053

[48] Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [J].

Heyman, Benjamin ;

Rizzieri, David ;

Adams, David J. ;

De Castro, Carlos ;

Diehl, Louis ;

Li, Zhiguo ;

Moore, Joseph ;

Beaven, Anne .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (10) :679-686

[49] A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma [J].

Maddocks, Kami ;

Christian, Beth ;

Jaglowski, Samantha ;

Flynn, Joseph ;

Jones, Jeffery A. ;

Porcu, Pierluigi ;

Wei, Lai ;

Jenkins, Cynthia ;

Lozanski, Gerard ;

Byrd, John C. ;

Blum, Kristie A. .

BLOOD, 2015, 125 (02) :242-248

[50] Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study [J].

Flowers, Christopher R. ;

Matasar, Matthew J. ;

Herrera, Alex F. ;

Hertzberg, Mark ;

Assouline, Sarit ;

Demeter, Judit ;

Mcmillan, Andrew ;

Mehta, Amitkumar ;

Opat, Stephen ;

Trneny, Marek ;

Musick, Lisa ;

Hirata, Jamie ;

Yang, Annie ;

Sehn, Laurie H. .

REVISTA CHILENA DE LITERATURA, 2024, (109) :1194-1205

← 1 2 3 4 5 →